Glenmark Pharmaceuticals is currently trading at Rs. 525.20, up by 0.50 points or 0.10% from its previous closing of Rs. 524.70 on the BSE.
The scrip opened at Rs. 527.95 and has touched a high and low of Rs. 527.95 and Rs. 525.00 respectively.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 957.50 on 22-Feb-2017 and a 52 week low of Rs. 517.40 on 19-Feb-2018.
Last one week high and low of the scrip stood at Rs. 532.05 and Rs. 517.40 respectively. The current market cap of the company is Rs. 14,819.00 crore.
The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 37.07% and 16.40% respectively.
Glenmark Pharmaceuticals has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.
It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the US brand sales for the six products was approximately $1.7 billion for calendar year 2017.
Glenmark Pharmaceuticals (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries.
